Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...